Keryx Biopharmaceuticals

Foresite closes $100M growth capital fund for late-stage healthcare companies

Friday, February 1, 2013

Foresite Capital Management, a growth equity firm founded by Jim Tananbaum to finance late-stage healthcare companies, has closed its $100 million fund, Foresite Capital Fund I. The firm draws on Tananbaum and his partners’ experience and expertise in building leading healthcare companies, as well as their broad private and public investment experience.

[Read More]

Keryx completes patient enrollment for phase III Zerenex trial

Monday, September 19, 2011

Keryx Biopharmaceuticals has completed patient enrollment in the long-term study component of its phase III registration program of Zerenex, the company’s ferric iron-based phosphate binder for the treatment of elevated serum phosphorus levels, or hyperphosphatemia, in patients with end-stage renal disease (ESRD) on dialysis. The Zerenex phase III registration program, which is being conducted pursuant to a Special Protocol Assessment (SPA) with the FDA, is comprised of an already successfully-completed phase III short-term study, and this ongoing phase III long-term study.

[Read More]